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Abstract: The frequency of visual gamma oscillations is determined by both the neuronal excitation–
inhibition balance and the time constants of GABAergic processes. The gamma peak frequency has
been linked to sensory processing, cognitive function, cortical structure, and may have a genetic contri-
bution. To disentangle the intricate relationship among these factors, accurate and reliable estimates of
peak frequency are required. Here, a bootstrapping approach that provides estimates of peak fre-
quency reliability, thereby increasing the robustness of the inferences made on this parameter was
developed. The method using both simulated data and real data from two previous pharmacological
MEG studies of visual gamma with alcohol and tiagabine was validated. In particular, the study by
Muthukumaraswamy et al. [2013a] (Neuropsychopharmacology 38(6):1105–1112), in which GABAergic
enhancement by tiagabine had previously demonstrated a null effect on visual gamma oscillations,
contrasting with strong evidence from both animal models and very recent human studies was re-
evaluated. After improved peak frequency estimation and additional exclusion of unreliably measured
data, it was found that the GABA reuptake inhibitor tiagabine did produce, as predicted, a marked
decrease in visual gamma oscillation frequency. This result demonstrates the potential impact of objec-
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INTRODUCTION
Synchronization of rhythmic neuronal firing in the
gamma range (30–90 Hz) is a potential mechanism for
information coding in the brain [Buzsaki and Wang, 2012;
Fries, 2009]. Pyramidal cell populations synchronized by
inhibitory gamma-aminobutyric acid (GABA)-ergic inter-
neurons produce intra-cortical local field potential (LFP)
oscillations [Gonzalez-Burgos and Lewis, 2012], which can
be recorded with high consistency between primates and
humans [Fries et al., 2008]. Through translational research
[Hall et al., 2005], gamma oscillations have been impli-
cated in human sensory and cognitive function, as well as
in neuropsychiatric disease [see Bosman et al., 2014; Phil-
lips and Uhlhaas, 2015; Sedley and Cunningham, 2013, for
reviews]. In the magnetoencephalographic (MEG) signal,
sustained narrow-band gamma oscillations are generated
in visual cortex in response to simple contrast pattern
stimuli [Adjamian et al., 2004; Hoogenboom et al., 2006].
These responses arise from the interaction between local
excitatory and inhibitory networks, which are believed to
shape the amplitude, as well as the peak frequency of
gamma oscillations [Bartos et al., 2007; Gonzalez-Burgos
and Lewis, 2012].
The peak frequency of visual gamma responses is
modulated by properties of the visual stimulus such as
size [Gieselmann and Thiele, 2008; Jia et al., 2013; Ray and
Maunsell, 2011; van Pelt and Fries, 2013], contrast [Hadji-
papas et al., 2015; Jia et al., 2013; Lowet et al., 2015; Perry
et al., 2015; Ray and Maunsell, 2010; Roberts et al., 2013],
motion [Friedman-Hill, 2000; Muthukumaraswamy and
Singh, 2013; Swettenham et al., 2009], motion velocity
[Gray et al., 1990; Gray and Viana Di Prisco, 1997; Ore-
khova et al., 2015], eccentricity [van Pelt and Fries, 2013],
noise masking [Jia et al., 2013], and cross-orientation mask-
ing [Lima et al., 2010; Perry, 2015]. Across individuals,
peak gamma frequency correlates with psychophysical
performance in visual discrimination tasks [Dickinson
et al., 2015; Edden et al., 2009]. Inter-individual differences
in frequency appear to be strongly genetically determined
[van Pelt et al., 2012], though the individual peak fre-
quency decreases with age [Gaetz et al., 2012; Muthuku-
maraswamy et al., 2010; Robson et al., 2015]. Nevertheless,
peak gamma frequency is highly reproducible over shorter
time scales, and thus represents a suitable measure for
within-subject designs [Muthukumaraswamy et al., 2010;
Swettenham et al., 2009].
In-vitro and in-vivo animal studies have demonstrated a
dependency of peak gamma frequency on the time con-
stants of GABAergic processes [Bartos et al., 2007;
Gonzalez-Burgos and Lewis, 2012]. In very recent years, a
limited number of studies combining MEG with pharma-
cological modulation of neurotransmission have provided
initial compelling evidence for the translation of such
models to humans. Reduced frequency of gamma oscilla-
tions was observed following administration of alcohol
[Campbell et al., 2014] and lorazepam [Lozano-Soldevilla
et al., 2014], drugs which enhance GABAergic transmission
through different mechanisms. These findings largely sup-
port animal models in which inhibitory post-synaptic cur-
rents (IPSCs) of prolonged duration result in synchronized
pyramidal neurons firing at slower rhythms, generating
gamma oscillations at lower frequencies and with higher
amplitudes [Gonzalez-Burgos and Lewis, 2012].
However, not all human studies are entirely consistent
with the animal literature. For example, the GABAA posi-
tive allosteric modulator propofol was found to increase
gamma amplitude, but left gamma frequency unchanged
[Saxena et al., 2013]. More surprisingly, a recent study
reported that neither the amplitude nor the frequency of
visual gamma responses were modulated by tiagabine
[Muthukumaraswamy et al., 2013a], a drug that prolongs
IPSC duration by selectively inhibiting the re-uptake of
GABA from the synapse. To date, the reasons behind such
inconsistencies remain unknown.
In the present work, we build upon previous research in
which the robustness of oscillatory measures in the
gamma range was studied with respect to systematic var-
iations of the stimulus configuration [Muthukumaraswamy
and Singh, 2013]. Despite the use of optimally designed
experimental paradigms, gamma responses in certain par-
ticipants can be barely detectable or scarcely quantifiable
[Hoogenboom et al., 2006; Muthukumaraswamy et al.,
2010]. Therefore, our ability to disentangle the relationship
between gamma oscillation frequency and other parame-
ters depends on the accurate and reliable estimation of
peak frequency. In particular, the inclusion of weakly esti-
mated parameters can lead to enhanced risk of both spuri-
ous findings and false negative results. For this reason, we
developed a novel approach to identify poor quality data
by means of un-biased procedures that identify confidence
intervals on the parameter estimates via bootstrapping.
Firstly, we test the method on simulated data, demonstrat-
ing its validity as well as its increased accuracy in peak
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frequency estimation. Secondly, we test the method on a
pharmacological MEG study of visual gamma and alcohol,
replicating the drug-induced reduction in peak gamma fre-
quency [Campbell et al., 2014]. Finally, we apply the
method to visual gamma data from the pharmacological
MEG study of tiagabine by Muthukumaraswamy et al.
[2013a]. Contrary to the null result previously reported,
we found that pharmacological enhancement of GABAer-
gic neurotransmission by tiagabine produced a marked
decrease in the peak frequency of visual gamma oscilla-
tions. The result supports the authors’ original predictions
[Muthukumaraswamy et al., 2013a], and provides addi-
tional translational evidence for the neurophysiological
mechanisms generating gamma oscillations in humans
[Bartos et al., 2007; Buzsaki and Wang, 2012].
MATERIALS AND METHODS
Quality Control Method Validation
Data simulation
We used Matlab (The MathWorks) to simulate electro-
physiological data, as they would be recorded in visual
gamma paradigms with MEG. The data resembled the
time course of source-reconstructed cortical activity in
the occipital lobe [see Muthukumaraswamy et al., 2010,
for an example with real data], and were generated on a
trial-by-trial basis (100 trials per dataset). Each trial was
composed of noise (2 s), sampled at 1,200 Hz, with 1/f
frequency scaling of the power spectrum. To reproduce
the sustained component of visual gamma responses, the
second half of each trial was embedded with a sinusoidal
signal (1 s), with different frequency in each trial. The
frequency of the oscillation was normally distributed
across trials, with both mean frequency and mode fre-
quency of 60 Hz, and standard deviation (SD) of fre-
quency increasing exponentially from 2.5 to 20 Hz across
six different conditions (Fig. 1). The six conditions were
used to represent the inter-individual variability in
gamma quality that is observed in real participants [e.g.,
Muthukumaraswamy et al., 2010]. The amplitude of the
oscillation was also normally distributed across trials
(mean5 10%, SD5 1%, relative to noise amplitude). The
phase of the oscillation was generated at random, to
avoid phase consistency across trials and reproduce the
induced component of visual gamma responses (i.e.,
time-locked but not phase-locked across trials). Thirty
datasets were generated in each SD condition. The distri-
bution of frequencies across trials differed slightly
between datasets, although it always conformed in mean,
mode, and SD, to the appropriate condition. Therefore,
by manipulating the consistency of gamma frequency,
while precisely controlling for other parameters, we cre-
ated an ideal scenario for testing the performance of our
method with data of progressively degraded quality. The
spectra derived with the Envelope and Bootstrap meth-
ods are shown in Figure 1C,D, respectively (see section
on “Spectral Analysis and Quality Control”). It can be
seen that as the SD of the response frequency increased,
the range of estimated peak frequencies across datasets
(gray background areas in Figure 1C,D) also increased.
Overall, the range of peaks estimated with the Bootstrap
method was smaller and closer to the real peak fre-
quency of the data, and hence this method was chosen
for subsequent analyses.
Spectral analysis and quality control
An overview of our approach to peak frequency estima-
tion and quality control (QC) is illustrated schematically in
Figure 2. To estimate peak gamma frequency, we per-
formed spectral analysis using a Fourier method, the
smoothed periodogram [Bloomfield, 2000]. In each trial,
the time series of baseline and stimulus (1 s each) were
demeaned and tapered with a Hanning window. The raw
periodogram was computed separately for baseline and
stimulus, and smoothed with a Gaussian kernel (SD5 2
Hz). The single-trial spectra were averaged across trials,
separately for baseline and stimulus, and the amplitude
spectrum was calculated as percentage signal change from
baseline. In a bootstrap procedure with 10,000 iterations,
trials were resampled (with replacement), the resampled
single-trial spectra were averaged, and peak gamma fre-
quency was measured as the spectral peak of greatest
increase from baseline, in the 30–90 Hz range. The distri-
bution of peak frequencies across bootstrap iterations was
then used in a QC procedure, which evaluated the reliabil-
ity of the estimated peak frequencies, by calculating the
width in frequency that was necessary to accommodate at
least 50% of the bootstrapped frequencies around the dis-
tribution mode.
The mean of the bootstrapped peak frequencies distri-
bution was used as an improved estimate of peak
gamma frequency. To test the validity of this measure,
hereafter simply referred to as “Bootstrap peak
frequency,” we compared its accuracy to a standard mea-
sure used in our lab, the “Envelope peak frequency.”
The Envelope peak frequency was calculated by
bandpass-filtering the individual frequencies between 30
and 90 Hz in steps of 0.5 Hz, then calculating the magni-
tude of the analytic signal (Matlab function: hilbert), to
yield the amplitude envelope for this frequency range.
The envelopes were baselined, in order to express the
response as a percentage change from baseline, and then
“stacked” to form a time-frequency spectrogram (Fig.
1B). From this spectrogram, amplitude was averaged
over the stimulus time-range, within each frequency,
yielding the average amplitude spectrum. This spectrum
can be used to estimate the peak frequency induced by
visual stimulation [see Muthukumaraswamy et al.,
2013a, for an example].
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Analysis of Alcohol MEG Data
Experimental design and data pre-processing
We re-analyzed data from a previous pharmacological
MEG study of alcohol [Campbell et al., 2014], using the
QC approach outlined above (see section on “Spectral
Analysis and Quality Control”). A detailed description of
the experimental procedures, including participants, exper-
imental design, MEG acquisition, and data analysis, are
reported in Campbell et al. [2014]. Here we provide a brief
summary. Sixteen healthy volunteers took part in a single-
blind, placebo-controlled, crossover study. The study was
divided into two days, each consisting of two sessions.
Figure 1.
Data simulation. (A) Distribution of simulated frequencies and
amplitudes pooled across all trials and all datasets, within each
of the six noise simulation conditions. Note the decrease in fre-
quency consistency across conditions. (B) Time-frequency spec-
trograms calculated as percentage change from baseline using
the Envelope method, averaged across trials and across datasets.
Warm colors index the percentage signal change from baseline,
with arbitrary units but the same scale across conditions. The
horizontal white line represents the real peak frequency in the
data, defined by mean and mode frequency across trials. (C)
Spectra of percentage signal change from baseline derived using
the Envelope method, by averaging across the time dimension
(0–1 s) of the time-frequency spectrograms. Within each condi-
tion, the colored shadings represent6 1 SD across datasets, the
thick vertical black lines represent peak gamma frequency, the
vertical dashed lines represent the upper and lower limit of the
frequency range in which peaks were searched, and the grey
background areas define the range of observed peaks across
datasets. (D) Spectra derived using the Bootstrap method, by
averaging the bootstrapped spectra calculated with the
smoothed periodogram. The colored shadings, the thick vertical
black lines, the vertical dashed lines, and the grey background
areas, are the same as in C. It can be noted that the range of
peaks estimated with the Bootstrap method (D) was smaller
and closer to the real peak frequency of the data, compared
with the Envelope method (C). [Color figure can be viewed in
the online issue, which is available at wileyonlinelibrary.com.]
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Each day began with a “pre-drink” session, followed by
either placebo or alcohol consumption (0.8 g/kg), and by a
“post-drink” session. In each session, MEG was recorded
while participants performed the same visual gamma par-
adigm as described in the tiagabine study (see section on
“Experimental Design and Data Pre-Processing”; [Muthu-
kumaraswamy et al., 2013a]). The only difference between
the two visual paradigms was the longer stimulus dura-
tion in the alcohol study (1.5 s) compared with the tiaga-
bine study (1 s). For each participant, virtual sensor time
series were reconstructed in the voxel of maximal gamma
(30–80 Hz) amplitude increase in the occipital lobe.
Alcohol data analysis and quality control
Peak gamma frequency reliability estimates and Boot-
strap peak frequency measures were obtained using the
QC method as described in the validation study (see sec-
tion on “Spectral Analysis and Quality Control”). The
analysis time-range was 21.4 to 20.1 s for baseline and
0.3–1.5 s for stimulation. The QC criterion was the same as
in the tiagabine analysis (1.2 Hz; see section on
“Tiagabine Data Analysis and Quality Control”). In other
words, if 50% or more of the bootstrapped peak frequen-
cies in a given dataset fell within 61.2 Hz of the bootstrap
distribution mode, peak frequency in that dataset was con-
sidered reliably estimated. Otherwise, the dataset was
marked as of poor quality.
Analysis of Tiagabine MEG Data
Experimental design and data pre-processing
We re-analyzed data from a previous pharmacological
MEG study of tiagabine [Muthukumaraswamy et al.,
2013a], using the QC approach outlined above (see section
on “Spectral Analysis and Quality Control”). A detailed
description of the experimental procedures, including par-
ticipants, experimental design, MEG acquisition, and data
analysis, are reported in Muthukumaraswamy et al.
[2013a]. Here we provide a brief summary. Fifteen healthy
volunteers took part in a single-blind, placebo-controlled,
crossover study. The study was divided into two days,
each consisting of four sessions. Each day began with a
“pre” measurement session, followed by oral administra-
tion of either placebo or tiagabine (15 mg; GabitrilVR ), and
by three “post” measurement sessions at 1, 3, and 5 hours
after ingestion. In each session, MEG was recorded while
participants performed a visual paradigm known to
robustly induce gamma oscillations in primary visual cor-
tex (stationary, maximum contrast, three cycles per degree,
square-wave grating). For each participant, the trial time
courses were reconstructed by generating a virtual sensor
in the voxel of maximal gamma (30–80 Hz) amplitude
increase in the occipital lobe. From this point onward, our
analysis departed from that described in Muthukumarasw-
amy et al. [2013a].
Figure 2.
Quality control method. Schematic illustration of the approach
to peak frequency estimation and quality control (QC).
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Tiagabine data analysis and quality control
Peak gamma frequency reliability estimates and Boot-
strap peak frequency measures were obtained using the
QC method as described in the validation study (see sec-
tion on “Spectral Analysis and Quality Control”). As the
baseline (20.8 to 20.1 s) and stimulus (0.3–1.0 s) analysis
time-range had a relatively short length of 700 ms, a rela-
tively broad tapered Tukey window (a5 0.25) was chosen
in order to reduce spectral leakage whilst preserving as
much of the signal as possible. The QC criterion used to
calculate a reliability measure was based on the frequency
resolution of the periodogram (1.2 Hz). In other words,
if 50% or more of the bootstrapped peak frequencies in a
given dataset fell within 61.2 Hz of the bootstrap distribu-
tion mode, peak frequency in that dataset was considered
reliably estimated. Otherwise, the dataset was marked as
of poor quality.
RESULTS
Method Validation
The QC analysis of the simulated data (see section on
“Data Simulation”) showed that, across the six conditions
of exponentially decreasing frequency consistency, the
width of the Bootstrap peak frequency distribution
increased monotonically (Fig. 3A). Likewise, we observed
a monotonic decrease in the percentage of bootstrap itera-
tions falling within 61.2 Hz of the bootstrap distribution
mode (Fig. 3B). This indicated the validity of the QC as a
method to obtain reliability estimates of peak gamma
frequency.
Next, we compared the accuracy in peak frequency esti-
mation between the Bootstrap peak frequency and the
Envelope peak frequency. As shown in Figure 3C, the
Bootstrap method performed better than the Envelope
method, with higher estimation accuracy particularly at
the lowest levels of gamma quality.
Alcohol Data
The QC analysis of the alcohol data (see section on
“Alcohol Data Analysis and Quality Control”) revealed
that the estimate of peak frequency did not meet our QC
reliability criterion in 5 out of 64 datasets (across all partic-
ipants and conditions; Fig. 4). This resulted in poor quality
data in 4 out of 16 participants, as also reported by Camp-
bell et al. [2014].
To test the effect of alcohol on the frequency of visual
gamma, peak frequency was analyzed using a 2 3 2
repeated measures ANOVA, with factors Drug (two levels:
placebo and alcohol) and Time (two levels: pre and post),
with the Drug 3 Time interaction term being of most inter-
est. To compare how the exclusion of participants and the
bootstrap approach to frequency estimation affected the
results, the analysis was repeated using the Bootstrap peak
frequency (Fig. 5A,B), and the Envelope peak frequency
(Fig. 5C,D), with inclusion of good quality data only (Fig.
5A,C), and with all data included (Fig. 5B,D). For refer-
ence, the interaction effect observed by Campbell et al.
Figure 3.
Results of method validation with simulated data. (A) Width of
the frequency range accommodating 50% or more bootstrapped
peaks around the bootstrap distribution mode. (B) Percentage
of bootstrapped peaks within 61.2 Hz of the distribution mode.
(C) Absolute difference between the real and the estimated
peak frequencies, averaged across datasets and plotted sepa-
rately for the Bootstrap (blue) and Envelope (green) estimation
methods. In all plots, shaded areas represent6 1 standard error
of the mean (SEM) across datasets. [Color figure can be viewed
in the online issue, which is available at wileyonlinelibrary.com.]
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Figure 4.
QC results of alcohol data. Distribution of bootstrapped peaks arranged column-wise by participants,
in the placebo (top two rows) and alcohol (bottom two rows) conditions. The QC results are dis-
played in red (poor datasets) and in blue (good datasets). List-wise exclusions are displayed in gray.
[Color figure can be viewed in the online issue, which is available at wileyonlinelibrary.com.]
Figure 5.
Peak frequency modulations with alcohol. Peak gamma frequency
calculated using the Bootstrap method, (A) after exclusion of
poor quality data, and (B) with all participants included. Peak
gamma frequency calculated using the Envelope method, (C)
after exclusion of poor quality data, and (D) with all participants
included. Peak frequency is plotted in blue for placebo and in
red for alcohol. Vertical bars represent 61 SEM. [Color figure
can be viewed in the online issue, which is available at wileyonli-
nelibrary.com.]
r Peak Gamma Frequency Reduction by Tiagabine r
r 7 r
[2014], where peak frequency was estimated in twelve par-
ticipants using skewed Gaussian function fits, was
F(1,11)5 13.31, P5 0.004.
The Bootstrap method in the 12 accepted participants,
illustrated in Figure 5A, resulted in no significant effect of
Drug (F(1,11)5 2.44, P5 0.15), a significant effect of Time
(F(1,11)5 5.34, P5 0.041), and a significant Drug 3 Time
interaction effect (F(1,11)5 15.58, P5 0.002). Peak fre-
quency was significantly reduced by alcohol in the post-
alcohol session compared with both the pre-alcohol
(t(11)524.68, P5 0.001) and the post-placebo session
(t(11)523.63, P5 0.004). There were no significant differ-
ences in peak frequency between pre- and post-placebo
(t(11)5 0.58, P5 0.57) or between pre-placebo and pre-
alcohol (t(11)5 0.44, P5 0.67). The absence of a significant
difference between pre- and post-placebo indicated that
the significant main effect of Time was driven by the sig-
nificant difference between pre- and post-alcohol alone.
The results of the Bootstrap method with inclusion of all
sixteen participants (Fig. 5B) showed no significant effect
of Drug (F(1,15)5 1.04, P5 0.32) or Time (F(1,15)5 0.31,
P5 0.59), and no significant Drug 3 Time interaction effect
(F(1,15)5 0.58, P5 0.46).
The Envelope method in the twelve accepted partici-
pants (Fig. 5C) resulted in no significant effect of Drug
(F(1,11)5 2.51, P5 0.14) or Time (F(1,11)5 2.30, P5 0.16),
and a significant Drug 3 Time interaction effect
(F(1,11)5 9.16, P5 0.012). Peak frequency was significantly
reduced by alcohol in the post-alcohol session compared
with both the pre-alcohol (t(11)522.57, P5 0.026) and the
post-placebo session (t(11)522.71, P5 0.020). There were
no significant differences in peak frequency between pre-
and post-placebo (t(11)5 0.22, P5 0.83) or between pre-
placebo and pre-alcohol (t(11)520.12, P5 0.91).
The results of the Envelope method with inclusion of all
16 participants (Fig. 5D) showed no significant effect of
Drug (F(1,15)5 0.40, P5 0.53) or Time (F(1,15)5 1.26,
P5 0.30), and no significant Drug 3 Time interaction effect
(F(1,15)5 0.05, P5 0.82).
To summarize, using the Bootstrap method to estimate
peak gamma frequency and after exclusion of participants
based on the QC approach, the interaction effect was repli-
cated at a higher level of significance compared with the
Envelope method and the Gaussian function fits. Further-
more, our QC approach resulted in the exclusion of four
participants, as also reported by Campbell et al. [2014]
based on the absence of a clear peak in at least one of the
conditions. No significant interaction was observed, with
either the Bootstrap or the Envelope method, when all par-
ticipants were included in the analysis.
Tiagabine Data
The QC analysis of the tiagabine data (see section on
“Tiagabine Data Analysis and Quality Control”) revealed
that the estimate of peak frequency did not meet our QC
reliability criterion in 22.5% of the datasets (across all par-
ticipants and conditions; Fig. 6). Across the eight measure-
ment sessions, the rate of within-subject data rejection was
as high as 62.5% in four participants. Poor quality datasets
were treated as missing observations, and excluded from
Figure 6.
QC results of tiagabine data. Distribution of bootstrapped peaks
arranged column-wise by participants, in the placebo (top four
rows) and tiagabine (bottom four rows) conditions. The QC
results are displayed in red (poor datasets) and in blue (good
datasets). List-wise exclusions are displayed in gray. The Boot-
strap peak frequency (mean of the distribution) is indicated with
a vertical line in each dataset. [Color figure can be viewed in the
online issue, which is available at wileyonlinelibrary.com.]
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further statistical analysis according to a list-wise deletion
approach.
To compare the spatial distribution of gamma responses
between placebo and tiagabine conditions, we averaged
the Synthetic Aperture Magnetometry (SAM [Robinson
and Vrba, 1999]) beamformer images, separately for
accepted and rejected participants. As shown in Support-
ing Information Figure S1, the SAM images did not show
any apparent difference between tiagabine and placebo, or
across measurement sessions. However, as expected, the
average amplitude of gamma in the occipital cortex
appears to be consistently higher in the accepted partici-
pants, compared with those whose data was rejected.
To test our main hypothesis of a shift in the frequency
of visual gamma, the Bootstrap peak frequency was ana-
lyzed in the eight accepted participants using a 2 3 4
repeated measures ANOVA, with factors Drug (two levels:
placebo and tiagabine) and Time (four levels: pre, 1 h, 3 h,
and 5 h). In this analysis design, a significant effect of tia-
gabine is demonstrated by a significant Drug 3 Time inter-
action. Results, illustrated in Figure 7A, showed a
significant effect of Drug (F(1,7)5 18.8, P5 0.003), a mar-
ginally non-significant effect of Time (F(3,21)5 2.9,
P5 0.057), and a significant Drug 3 Time interaction effect
(F(3,21)5 3.7, P5 0.028).
To investigate the temporal profile of drug modulation,
given the significant interaction, we analyzed the simple
effects of Drug using paired-sample t tests at each of the
four time points. There was no difference in peak gamma
frequency between the pre-ingestion sessions of the tiaga-
bine and placebo treatments (t(7)520.2, P5 0.87). In con-
trast, peak gamma frequency was significantly reduced
with tiagabine, compared with the corresponding placebo
sessions, at 1 h (t(7)5 2.4, P5 0.048), at 3 h (t(7)5 6.5,
P5 0.0003), and at 5 h post-ingestion (t(7)5 5.0, P5 0.002).
Next, we analyzed the simple effects of Time with two 1
3 4 repeated measures ANOVAs, separately for each of
the two treatments. There was no effect of time in the
Figure 7.
Peak frequency modulations with tiagabine. Peak gamma fre-
quency calculated using the Bootstrap method, (A) after exclu-
sion of poor quality data, and (B) with all participants included.
Peak gamma frequency calculated using the Envelope method,
(C) after exclusion of poor quality data, and (D) with all partici-
pants included. Peak frequency is plotted in black for placebo
(PLC) and in red for tiagabine (TGB). Vertical bars represent
61 SEM. [Color figure can be viewed in the online issue, which
is available at wileyonlinelibrary.com.]
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placebo treatment (F(3,21)5 0.1, P5 0.97), suggesting that
peak frequency was estimated reliably over repeated ses-
sions under administration of placebo. In contrast, the
effect of Time was significant in the tiagabine treatment
(F(3,21)5 7.3, P5 0.002). Compared with the pre-tiagabine
session, peak gamma frequency was significantly reduced
at 1 h (t(7)5 2.6, P5 0.036), at 3 h (t(7)5 5.2, P5 0.001),
and at 5 h post-tiagabine (t(7)5 5.5, P5 0.001).
Subsidiary to our main hypothesis, we tested the effect
of tiagabine on gamma amplitude with the same statistical
analysis used for peak gamma frequency (i.e., a 2 3 4
repeated measures ANOVA in the eight accepted partici-
pants). As suggested by visual inspection of the SAM spa-
tial images (Supporting Information Fig. S1), results
showed no significant effect of Drug (F(1,7)5 1.7, P5 0.24),
or Time (F(3,21)5 1.5, P5 0.24), and no significant Drug 3
Time interaction (F(3,21)5 2.6, P5 0.08). The amplitude
spectra of percentage change from baseline in the gamma
range are illustrated in Figure 8, averaged across partici-
pants. The correspondence between the Bootstrap peak fre-
quencies and the peaks in the gamma range of the raw
spectra, across all participant and conditions, is illustrated
in Supporting Information Figure S2.
Overall, these results indicated that peak gamma fre-
quency was significantly reduced by tiagabine at each of
the three time points measured after drug administration,
whereas gamma amplitude was not affected. Furthermore,
peak frequency did not differ statistically across the four
measurements in the placebo conditions, or between the
pre-tiagabine and the pre-placebo sessions. Therefore,
peak frequency was estimated reliably both at repeated
intervals of 2 h, and between sessions as far as 1 week
apart. For comparison, results are shown in Figure 7 after
the analysis was repeated using the Bootstrap peak fre-
quency (Fig. 7A,B), and the Envelope peak frequency (Fig.
7C,D), with inclusion of good quality data only (Fig.
7A,C), and with all data included (Fig. 7B,D). Despite the
session of maximal decrease in frequency differed among
the four combinations of method and sample used, the
pattern of results appeared qualitatively comparable, apart
from when the Envelope method was used with inclusion
of all participants.
Additionally, we asked the question of whether differen-
ces in gamma quality could be related to differences in the
individual peak gamma frequency, across participants.
The latter measure has been proposed as an index of local
Figure 8.
Tiagabine spectra. Amplitude spectra of percentage change from
baseline averaged over participants (n5 8). Shaded areas repre-
sent 61 SEM across participants. Vertical bars indicate the Boot-
strap peak frequency average in the pre- (blue) and post-drug
sessions of placebo (PLC; black) and tiagabine (TGB; red). Note
that the averaged Bootstrap peaks (vertical lines) appear left of
the peak in the averaged spectra because of the averaging proce-
dure, particularly in the right-hand panels. Specifically, the indi-
vidual spectra of higher amplitude tended to peak at higher
frequencies, resulting in increased amplitude of the portion of
the spectrum on the right side of the average peak frequency.
[Color figure can be viewed in the online issue, which is avail-
able at wileyonlinelibrary.com.]
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GABA concentration [Muthukumaraswamy et al., 2009]
and GABAA receptor density [Kujala et al., 2015], two fac-
tors that could potentially influence the variability of our
peak frequency reliability estimates. We used Pearson’s r
coefficient to correlate peak gamma frequency, in each
experimental session, with peak frequency reliability, as
measured by the percentage of bootstrap iterations within
61.2 Hz of the bootstrap distribution mode. As illustrated
in Supporting Information Figure S3A, we found no evi-
dence for a consistent relationship between these two
measures, suggesting that the estimated reliability of peak
gamma frequency does not depend on the frequency at
which gamma peaks occur.
Finally, we investigated the relationship between the
magnitude of the change in peak frequency and gamma
quality. We first calculated the change in peak frequency
by subtracting the pre-placebo (or pre-tiagabine) peak fre-
quency from each of the post-placebo (or post-tiagabine)
sessions, and then correlated this measure with peak fre-
quency reliability. For this purpose, the percentage of
bootstrap iterations in the “pre” and “post” sessions were
averaged, separately for each correlation. Once again, we
found no significant correlations between peak frequency
reliability and drug-induced change in peak frequency.
The correlation at 1 h post-tiagabine was the only positive
correlation, and its uncorrected p-value approached statis-
tical significance (r5 0.48, P5 0.067). As illustrated in Sup-
porting Information Figure S3B (bottom row, first plot
from the left) participants whose peak gamma frequency
decreased the most tended to show the lowest reliability
estimates, at 1 h post-tiagabine. This would explain why,
after participant exclusion, the greatest reduction in peak
frequency was observed in the session at 3 h, rather than
1 h after tiagabine (cf. Fig. 7A,B).
DISCUSSION
The true nature of neuronal oscillations in the gamma
frequency range has been long disputed in neuroscience
[Brunet et al., 2014b]. Correspondingly, the choice of spec-
tral method for the analysis of electrophysiological data
has also been highly debated [Bruns, 2004; Le Van Quyen
and Bragin, 2007; Le Van Quyen et al., 2001; van Vugt
et al., 2007]. In the first part of this work, we developed a
method based on bootstrapping across trials, which served
two purposes. Firstly, we used a measure of spread in the
distribution of bootstrapped peaks to estimate the reliabil-
ity of peak gamma frequency, which in turn allowed the
identification of poorly estimated data. Secondly, we meas-
ured peak gamma frequency by averaging across the boot-
strapped samples, and demonstrated the increased
robustness of this measure relative to a more conventional
alternative method. In the second part, we used the QC
method to re-analyze data from two pharmacological
MEG studies, one in which alcohol was demonstrated to
produce a marked decrease in the peak frequency of vis-
ual gamma oscillations [Campbell et al., 2014], and one in
which tiagabine was reported to modulate stimulus-
evoked responses, but to have no effect on neuronal oscil-
latory dynamics [Muthukumaraswamy et al., 2013a].
Methodological Considerations
The QC approach presented here should be considered
as a framework for objective quantification of data quality.
This neither establishes fixed criteria, nor provides rigid
guidelines for data exclusion. Rather, by characterizing
data quality with descriptive measures, the method can be
used to define explicit exclusion criteria based on unam-
biguous thresholds, and could prove useful for comparing
data across sites, studies, and designs. The Bootstrap peak
frequency, calculated from the bootstrap distribution,
resulted in an optimal measure when inter-trial frequency
consistency was low in our method validation. However,
it is possible that other methods, such as the Envelope
approach, could perform with better accuracy under dif-
ferent circumstances, such as when oscillation frequency
cannot be assumed stationary. Furthermore, future work
on either simulated data or large-sample datasets will
have the opportunity to optimize the current method by
using a systematic approach to vary the parameters of
each method (e.g., spectral estimation, tapering, number of
iterations and jackknife resampling, bootstrap width crite-
rion, etc.) and test how each of these changes impacts on
the sensitivity and specificity of the QC results. In particu-
lar, sensitivity and specificity can be affected by the width
criterion, which determines the threshold for data exclu-
sion. If a strict criterion is chosen, good but not perfect fre-
quency estimates could be inappropriately excluded,
potentially leading to a loss of statistical power. On the
contrary, the choice of a loose criterion could lead to inclu-
sion of poor estimates and, for example, increased likeli-
hood of false negative results. While the criterion was
chosen arbitrarily in this work, with its adequacy being
established by visual inspection of the bootstrap distribu-
tions, the use of empirically determined criteria in the
future would be desirable.
In the second part of this work, the alcohol data by
Campbell et al. [2014] was considered as a benchmark to
test the validity of our approach on real data. In the origi-
nal publication, the peak frequency and amplitude param-
eters were estimated by fitting skewed Gaussian functions
to the gamma range of the power spectra. In our analysis,
the success of the QC approach was demonstrated in two
ways. Firstly, it revealed the presence of poor quality data
in the same number of participants as originally reported
by the authors, who blind-screened the data for low-
amplitude gamma responses with no clear peak [Campbell
et al., 2014]. Secondly, it replicated the drug-induced mod-
ulations, consisting of a decrease in the peak frequency of
visual gamma with alcohol. Together, the results of our
validation study on simulated data and our replication of
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the findings by Campbell et al. [2014] supported the valid-
ity of our method to fulfill two purposes; firstly, to iden-
tify reliably measured data in the study by
Muthukumaraswamy et al. [2013a] and, secondly, to re-
test the effect of tiagabine using optimal estimates of peak
gamma frequency.
It should be noticed that, by applying a standard analy-
sis pipeline and avoiding participant exclusion, Muthuku-
maraswamy et al. [2013a] adopted the least biased
approach possible. On the one hand, the rejection of com-
plete datasets is particularly questionable when each indi-
vidual represents a precious or rare observation and the
sample size cannot be readily increased. On the other
hand, however, our proposed approach offers the advant-
age of basing statistical inference on reliably estimated fre-
quency measures. Furthermore, it circumvents the limits
of setting simple rejection criteria based on the amplitude
of the response, which would show a biased tendency to
remove sources of interesting variance, such as drug-
induced reductions in amplitude or disease-related impair-
ments of oscillatory rhythms.
Of course, rejecting datasets based on reliability of peak
frequency estimation is still dependent on signal-to-noise
and hence amplitude (although amplitude and frequency
have been shown to be at least in part dissociated [see Jia
et al., 2013]), but not as strongly as if amplitude criteria
were used. Put another way, any QC approach is vulnera-
ble to low generalizability of results, as the frequency
reduction induced by tiagabine can be demonstrated only
for those participants who showed gamma responses of
high consistency across trials. Despite the comparability of
results illustrated in Figure 7A,B, gamma measures must
be of sufficient quality in order for peak frequency modu-
lations to be statistically significant. Results, instead, can-
not be generalized to individuals who showed high inter-
trial variability in their response frequency. The factors
underlying such differences in the variability of the
gamma response frequency are largely unexplored, and
remain an open question for future research.
Peak Gamma Frequency Reduction by Tiagabine
After identification and exclusion of datasets that
yielded unreliable estimates of peak gamma frequency, we
observed a marked tiagabine-induced reduction in visual
gamma frequency. Peak frequency appeared to be signifi-
cantly reduced both at 1 h and at 3 h after oral administra-
tion (see section on “Tiagabine Data”), in line with the
pharmacokinetics of tiagabine showing maximum plasma
concentrations occurring between 45 and 150 min after
drug ingestion [Leach and Brodie, 1998; Murphy, 2011;
Snel et al., 1997]. The average decrease in frequency
induced by tiagabine, measured with the Bootstrap
method (Fig. 7A) relative to a pre-tiagabine peak fre-
quency of 52.96 5.0 Hz (mean6 SD across participants),
was 2.8, 4.1, and 3.8 Hz at 1, 3, and 5 h, respectively. Inter-
estingly, a comparable effect was observed with alcohol,
with peak frequency being reduced on average by 2.4 Hz
at less than 1 h after drug consumption, relative to a pre-
alcohol peak frequency of 52.66 5.9 Hz (Fig. 5A).
Overall, these novel tiagabine results are strongly sup-
ported by animals models, which demonstrate a close
dependency of gamma frequency on the time constants of
GABAergic inhibition [Faulkner et al., 1998; Oke et al.,
2010; Traub et al., 1996; Whittington et al., 1995, 1996; Xing
et al., 2012]. In relatively simple models, the generative
mechanisms of gamma oscillations consist of pyramidal
cells firing synchronously under the inhibitory control of
GABAergic interneurons [see Bartos et al., 2007; Buzsaki
and Wang, 2012; Gonzalez-Burgos and Lewis, 2012; Tie-
singa and Sejnowski, 2009, for reviews]. At the synaptic
level, tiagabine exerts its effects by selectively inhibiting
GAT-1, the most abundantly expressed GABA transporter
(GAT) in the cerebral cortex [Borden et al., 1994; Conti
et al., 2004]. By blocking the reuptake of GABA from the
synapse, tiagabine elevates the synaptic concentrations of
GABA [Dalby, 2000; Fink-Jensen et al., 1992] and increases
the duration of the GABAA receptor-induced IPSCs [Roep-
storff and Lambert, 1994; Thompson and G€ahwiler, 1992].
Thus, IPSCs of prolonged duration result in synchroniza-
tion of neuronal firing at slower rhythms, which in turn
translates to LFP oscillations at lower gamma frequencies.
Relationship Between Gamma and GABA
In non-invasive human studies, the use of magnetic res-
onance spectroscopy (MRS) to measure the relationship
between GABA and gamma frequency has produced con-
troversial results [cf. Cousijn et al., 2014; Muthukumarasw-
amy et al., 2009]. Invigorating this debate, a very recent
flumazenil-positron emission tomography (PET) study
demonstrated a positive correlation between the frequency
of visually induced gamma oscillations and the density of
GABAA receptors in early visual areas [Kujala et al., 2015].
Further contribution to the translation of animal models to
humans has come from studies combining MEG, to record
cortical activity, with the use of pharmacological agents, to
modulate neurotransmission [Hall et al., 2010; Muthuku-
maraswamy, 2014]. Decreased visual gamma frequency in
humans was observed after administration of alcohol,
which affects GABA and N-Methyl-D-aspartate (NMDA)
receptor activity [Campbell et al., 2014], and lorazepam, a
positive allosteric GABAA modulator [Lozano-Soldevilla
et al., 2014]. More recently, comparable results were
obtained with the NMDA receptor antagonist ketamine
[Shaw et al., 2015]. In addition to the frequency modula-
tion, these studies found increased amplitude of gamma
responses with GABAergic enhancement, replicating pre-
vious results obtained with administration of the GABAA
agonist propofol [Saxena et al., 2013]. Increased gamma
amplitude accompanying a shift toward lower gamma fre-
quencies may be related to the recruitment of larger
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pyramidal cell populations achieved under longer periods
of inhibition [Gonzalez-Burgos and Lewis, 2012].
In the current study, however, no significant effects
were observed when, subsidiary to our main hypothesis,
gamma amplitude was tested with the same analysis used
for peak frequency. This could suggest that tiagabine has a
specific effect on oscillation frequency via modulation of
inhibitory time constants, while leaving other network
parameters unaltered. In support of this, animal studies
have demonstrated that the duration of IPSCs is prolonged
by tiagabine, but IPSC amplitude is not increased [Roep-
storff and Lambert, 1994; Thompson and G€ahwiler, 1992].
Alternatively, the absence of an effect of drug on gamma
amplitude might be explained by lack of sensitivity of
amplitude measures themselves. Compared with gamma
frequency, gamma amplitude could be more vulnerable to
noise, particularly when differences in head movement or
head distance from the sensor array in repeated recording
sessions are not explicitly controlled for.
Relationship between Gamma Frequency and
Other Parameters
A partially unresolved question is whether the changes
in frequency associated with GABAergic neurotransmis-
sion are unique to gamma oscillations, or extend to other
frequency ranges. Likewise, it is unclear whether the
GABAergic influences on oscillatory dynamics are specific
to visual areas or extend to other cortices. In sensorimotor
regions, administration of a benzodiazepine GABAA posi-
tive allosteric modulator produced an alteration of the
beta rhythm consisting of decreased frequency and
increased amplitude [Jensen et al., 2005]. In other studies,
no differences in gamma frequency were observed over
motor regions using alcohol [Campbell et al., 2014], loraze-
pam [Lozano-Soldevilla et al., 2014], ketamine [Shaw et al.,
2015], or tiagabine [Muthukumaraswamy et al., 2013b].
Overall, therefore, the functional significance of shifts in
oscillation frequency remains a subject of significant
interest.
The frequency of gamma oscillations has been previ-
ously related to differences in behavioral performance
[Dickinson et al., 2015; Edden et al., 2009], and in cognitive
traits of possible clinical relevance [Dickinson et al., 2015;
Kahlbrock et al., 2012]. For example, a recent study
showed that the normal velocity-dependent modulation of
visual gamma frequency appeared to be impaired in chil-
dren with autism spectrum disorders [Stroganova et al.,
2015]. Although inter-individual differences in visual
gamma frequency have been related to the structural prop-
erties of visual cortical areas [e.g., Muthukumaraswamy
et al., 2010; Schwarzkopf et al., 2012], other studies do not
show a clear dependence [c.f. Kujala et al., 2015; Robson
et al., 2015]. Gamma frequency in visual cortex is modu-
lated by sensory input strength, increasing monotonically
with respect to stimulus contrast [Perry, 2015; Perry et al.,
2015; Ray and Maunsell, 2010]. Increased peak gamma fre-
quency has been reported also for stimuli of smaller size,
in both LFP [Gieselmann and Thiele, 2008; Ray and Maun-
sell, 2011] and MEG recordings [van Pelt and Fries, 2013;
although, see Perry et al., 2013 for inconsistent results].
This could be explained with smaller stimuli being repre-
sented by smaller neuronal ensembles, which in turn
could be synchronized at a higher frequency over a shorter
cortical distance [Gieselmann and Thiele, 2008]. Interest-
ingly, gamma responses in monkey visual areas are
induced at higher frequencies in response to repeated
stimulus presentations compared with novel stimuli [Bru-
net et al., 2014a], and functionally synchronous networks
appear to be tuned to higher frequencies when represent-
ing stimuli that are under the focus of attention [Bosman
et al., 2012; see also Fries et al., 2001; Fries, 2015]. How-
ever, attentional modulation of narrow-band gamma fre-
quency has not been observed with MEG [e.g., Koelewijn
et al., 2013], perhaps due to the different sensitivity of
MEG compared with LFPs.
CONCLUSIONS
The work presented here highlights the potential impact
of objective data quality quantification and paves the way
for future methodological developments in this direction.
Using a novel approach to peak frequency estimation, we
demonstrated a reduction in gamma frequency by tiaga-
bine, in those participants with reliable peak frequency
estimates. The result is supported by animal models, and
provides additional translational evidence of the GABAer-
gic mechanisms generating gamma oscillations in humans.
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